Tissue monoamine levels assessed postmortem by HPLC
| Control monoamine levels (pmol/mg) | Decrease in OFC DA-depleted monkeys (%) | |||||
|---|---|---|---|---|---|---|
| DA | 5-HT | NA | DA | 5-HT | NA | |
| OFC | 0.33 ± 0.06 | 0.83 ± 0.32 | 1.05 ± 0.12 | 45.5 ± 7.9* | 10.53 ± 20.9 | 48.4 ± 5.3* |
| Medial PFC | 0.35 ± 0.01 | 0.89 ± 0.21 | 1.25 ± 0.06 | 59.1 ± 2.38* | 8.29 ± 23.1 | 28.4 ± 12.5 |
| Lateral PFC | 0.29 ± 0.03 | 0.69 ± 0.15 | 0.99 ± 0.06 | 18.18 ± 11.4 | 15.9 ± 26.04 | 36.6 ± 11.5* |
| Dorsal PFC | 0.51 ± 0.06 | 0.51 ± 0.13 | 1.24 ± 0.10 | 10.3 ± 14.3 | 11.6 ± 18.13 | 28.13 ± 10.1 |
| Motor cortex | 0.44 ± 0.05 | 0.55 ± 0.11 | 1.44 ± 0.03 | 14.1 ± 24.4 | 8.3 ± 10.21 | 9.901 ± 7.4 |
| Amygdala | 6.33 ± 1.68 | 2.69 ± 0.66 | 1.76 ± 0.36 | 35.9 ± 8.14 | 18.3 ± 23.01 | 35.4 ± 13.8 |
| Nucleus Accumbens | 27.7 ± 7.29 | 2.55 ± 1.16 | 4.69 ± 1.11 | 18.6 ± 14.03 | −18.6 ± 35.01 | 33.3 ± 12.0 |
| Caudate: medial head | 50.06 ± 8.6 | 0.91 ± 0.12 | 0.37 ± 0.11 | −29.7 ± 21.9 | −31.3 ± 42.7 | 38.4 ± 10.6 |
| Caudate: lateral head | 51.2 ± 6.23 | 0.99 ± 0.28 | 0.38 ± 0.07 | −5.88 ± 20.3 | −2.39 ± 11.8 | 56.5 ± 5.55 |
| Caudate: body | 70.3 ± 8.9 | 1.15 ± 0.32 | 0.37 ± 0.11 | −7.38 ± 4.3 | 1.505 ± 5.2 | 28.7 ± 19.4 |
| Putamen | 69.3 ± 10.8 | 1.43 ± 0.36 | 0.52 ± 0.07 | 0.43 ± 4.22 | −5.52 ± 11.7 | −1.36 ± 12.6 |
Absolute levels of DA, 5-HT, and NA in the striatum, amygdala, and anterior cortices of sham-operated control marmosets (pmol/mg, mean ± SEM), and corresponding decreases in marmosets with 6-OHDA infusions into the OFC (percentage decrease from the sham-operated control group, mean ± SEM; negative changes indicate percentage increases);
↵*p < 0.05 for the group difference (from direct comparison of raw values from sham-operated and 6-OHDA-lesioned groups).